TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06940440: IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

Sponsor: TuHURA Biosciences, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,392,928

Rescue Site Savings

+$2,230,536

Unlock Full NCT06940440 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06940440 Rescue Dossier →